Daniel S Berger

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet · 2009 · 620 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Joseph J. Eron, Benjamin Young, David A. Cooper et al. · The Lancet · 2010 · 314 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

THE SUNBURNING ULTRAVIOLET METER: DESIGN AND PERFORMANCE

Daniel S Berger · Photochemistry and Photobiology · 1976 · 239 citations

Natural Sciences, Dermatology, Radiation Detection +16

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 228 citations

Life Sciences, Pharmacology, Pharmacotherapy +17

Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects

Joel E. Gallant, Allan Rodríguez, Winkler G. Weinberg et al. · The Journal of Infectious Diseases · 2005 · 147 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +11